Tuomo Tapani Pätsi
Chairman at FARON PHARMACEUTICALS OY
Net worth: 43 594 $ as of 2024-03-30
Profile
Tuomo Tapani Pätsi is currently the Chairman at Faron Pharmaceuticals Oy and Notable Labs Ltd.
He previously worked as the Co-Managing Director at Juno Therapeutics GmbH, Director at Celgene Ltd., Director at Celgene Europe Ltd., Vice President-European Region at Human Genome Sciences, Inc., Executive VP-Commercial International at Seagen Inc., and President-Europe, Middle East & Africa Region at Celgene International SARL.
He graduated from the University of Helsinki.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
FARON PHARMACEUTICALS OY
0.04% | 2024-04-02 | 25,098 ( 0.04% ) | 43 594 $ | 2024-03-30 |
Tuomo Tapani Pätsi active positions
Companies | Position | Start |
---|---|---|
FARON PHARMACEUTICALS OY | Chairman | 2024-04-04 |
Former positions of Tuomo Tapani Pätsi
Companies | Position | End |
---|---|---|
SEAGEN INC. | Corporate Officer/Principal | 2022-02-03 |
Celgene Ltd.
Celgene Ltd. Pharmaceuticals: MajorHealth Technology Celgene Ltd. engages in the development of human pharmaceuticals and agrochemicals. It focuses on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. The company was founded on June 2, 2015 and is headquartered in Uxbridge, the United Kingdom. | Director/Board Member | 2020-04-29 |
Juno Therapeutics GmbH
Juno Therapeutics GmbH BiotechnologyHealth Technology Part of Bristol Myers Squibb Co., Juno Therapeutics GmbH is a German company that researches and develops cellular therapies. The company is based in Munich, Germany. The CEOs of the private company are David Walter Pignolet, Lothar Germeroth. Juno Therapeutics was acquired by Juno Therapeutics, Inc., part of Bristol Myers Squibb Co. from March 07, 2018 on May 11, 2015 for $232.80 million. | Chief Executive Officer | - |
Celgene Europe Ltd.
Celgene Europe Ltd. BiotechnologyHealth Technology Part of Bristol Myers Squibb Co., Celgene Europe Ltd. is a British company that engages in research and development in pharmaceutical products. The private company is based in Middlesex, UK. | Director/Board Member | - |
Celgene International SARL
Celgene International SARL Pharmaceuticals: MajorHealth Technology Founded in 2010, Celgene International SARL is a Swiss bio-pharmaceutical company that operates to discover, develop, and commercialize therapies for unmet medical needs in cancer. Part of Bristol Myers Squibb Co., the private company is based in Boudry, Switzerland. | Corporate Officer/Principal | - |
Training of Tuomo Tapani Pätsi
University of Helsinki | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
FARON PHARMACEUTICALS OY | Health Technology |
Private companies | 6 |
---|---|
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Health Technology |
Seagen Inc.
Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
Celgene International SARL
Celgene International SARL Pharmaceuticals: MajorHealth Technology Founded in 2010, Celgene International SARL is a Swiss bio-pharmaceutical company that operates to discover, develop, and commercialize therapies for unmet medical needs in cancer. Part of Bristol Myers Squibb Co., the private company is based in Boudry, Switzerland. | Health Technology |
Juno Therapeutics GmbH
Juno Therapeutics GmbH BiotechnologyHealth Technology Part of Bristol Myers Squibb Co., Juno Therapeutics GmbH is a German company that researches and develops cellular therapies. The company is based in Munich, Germany. The CEOs of the private company are David Walter Pignolet, Lothar Germeroth. Juno Therapeutics was acquired by Juno Therapeutics, Inc., part of Bristol Myers Squibb Co. from March 07, 2018 on May 11, 2015 for $232.80 million. | Health Technology |
Celgene Ltd.
Celgene Ltd. Pharmaceuticals: MajorHealth Technology Celgene Ltd. engages in the development of human pharmaceuticals and agrochemicals. It focuses on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. The company was founded on June 2, 2015 and is headquartered in Uxbridge, the United Kingdom. | Health Technology |
Celgene Europe Ltd.
Celgene Europe Ltd. BiotechnologyHealth Technology Part of Bristol Myers Squibb Co., Celgene Europe Ltd. is a British company that engages in research and development in pharmaceutical products. The private company is based in Middlesex, UK. | Health Technology |
- Stock Market
- Insiders
- Tuomo Tapani Pätsi